ArcoScreen is a Swiss medtech is developing a new microfluidic discovery platform for drug screening targeting cell membrane receptors.
ArcoScreen has raised $100K in total funding. The most recent round was Debt Financing. The last funding was announced in October 2022.
ArcoScreen's investors include Venture Kick, Foundation for Innovation and Technology (FIT).
ArcoScreen is headquartered in Lausanne, Switzerland.
ArcoScreen is a Swiss medtech is developing a new microfluidic discovery platform for drug screening targeting cell membrane receptors.
ArcoScreen is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ArcoScreen — Funding & Investors." VCBacked, October 12, 2022, https://www.vcbacked.co/company/arcoscreen. Accessed August 14, 2026.
VCBacked. (2022). ArcoScreen — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/arcoscreen
{{cite web |title=ArcoScreen — Funding & Investors |url=https://www.vcbacked.co/company/arcoscreen |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated